Inhibitory effect of triamcinolone acetonide on corneal neovascularization

Murata, Masatoshi; Shimizu, Shinji; Horiuchi, Saburo; Taira, Masayuki

doi:10.1007/s00417-005-0036-1

Cited by 41 publications

(25 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Various compounds like steroids [17,18] , nonsteroidal anti-inflammatory drugs [19,20] , heparin [20] , natural extracts [15,16] , cyclosporine A [21] , methotrexate [22] , and different therapies like argon laser treatment and photodynamic therapy [23] have been used in experimental and clinical studies for treatment and prevention of corneal neovascularization. All these treatment options used in corneal neovascularization are not ideal treatments because of side effects like thermal injury to adjacent areas, ocular hypertension, cataract formation and vessel recanalization [16] .…”

Section: Discussionmentioning

confidence: 99%

Inhibitory Effects of SU5416, a Selective Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor, on Experimental Corneal Neovascularization

Keskın

Totan²,

Karadağ³

et al. 2011

Ophthalmic Res

View full text Add to dashboard Cite

Purpose: Treatment of neovascularization in ocular diseases with vascular endothelial growth factor (VEGF) inhibition shows promising results. SU5416 is a low-molecular-weight tyrosine kinase inhibitor. It selectively inhibits the membrane-bound tyrosine kinase activity of VEGF-2 receptor (Flk-1/KDR) and blocks the intracellular signaling process. The aim of this study was to evaluate the effect of SU5416 on corneal neovascularization. Methods: Corneas were cauterized with silver nitrate/potassium nitrate sticks in 20 eyes of 20 BALB/C mice. In the study group (n = 10), SU5416 (25 mg/kg) dissolved in dimethyl sulfoxide was given as an intraperitoneal injection in a single daily dose for 7 days. The other group of 10 mice given intraperitoneal dimethyl sulfoxide alone served as a control group. After 7 days, corneal neovascularization was evaluated using photographs captured by fluorescein angiography. Colored photographs were taken by a biomicroscope with a digital camera. Data were expressed as mean neovascular length and mean number of new vessels for each animal. The values were computed and compared between the groups. Results: The mean burn stimulus intensities were not different between the groups. In the study group, the mean length of the vessels and the mean number of vessels were 0.49 ± 0.05 and 11.20 ± 1.69 mm, respectively. In the control group, the mean length of the vessels and the mean number of the vessels were 0.89 ± 0.11 and 17.80 ± 1.03 mm, respectively. There is a statistically significant difference in the mean length and the mean number of new vessels between the study and control groups (p < 0.001). Conclusion: Selective inhibition of VEGFR-2 (Flk-1/KDR) tyrosine kinase with SU5416 was shown to have an inhibitory effect on corneal neovascularization in this animal model. VEGFR-2 (Flk-1/KDR) tyrosine kinase inhibition may represent a different pathway for treatment of the neovascularization process in ocular pathologies. Fluorescein angiography photographs of new vessels on the cornea may provide a better evaluation of neovascularization than colored images in animal models.

show abstract

Section: Discussionmentioning

confidence: 99%

Inhibitory Effects of SU5416, a Selective Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor, on Experimental Corneal Neovascularization

Keskın

Totan²,

Karadağ³

et al. 2011

Ophthalmic Res

View full text Add to dashboard Cite

show abstract

“…We have read the insightful laboratory investigation by Mutara et al [1] in the February 2006 issue of Graefes Archive for Clinical and Experimental Ophthalmology with interest. While their comments concerning the prevention of corneal neovascularization with triamcinolone acetonide were well received, we would like to take this opportunity to comment on the experimental protocol used in this study.…”

Section: Sirmentioning

confidence: 97%

Drug delivery to the eye through systematic circulation following subconjonctival injection

Erdurmuş

Durmuş

2006

Graefes Arch Clin Exp Ophthalmol

View full text Add to dashboard Cite

“…cyclosporin A, have been used for the treatment of corneal neovasculature, but established therapeutic methods are not currently available [16,17,18,19,20,21]. …”

Section: Discussionmentioning

confidence: 99%

Topical and Subconjunctival Bevacizumab for Corneal Neovascularization in an Experimental Rat Model

et al. 2012

View full text Add to dashboard Cite

Aims: To evaluate and compare the inhibitory effects of topical and subconjunctival bevacizumab on corneal neovascularization in a rat model. Methods: Twenty corneas of 20 rats were chemically cauterized with silver nitrate sticks. Animals were randomized into four groups: a control group that received only topical artificial tear drops twice daily, a subconjunctival injection group that received 1.25 mg (0.05 ml) of bevacizumab on the 1st, 4th, and 7th day, and two topical bevacizumab groups that received instillation of 4 or 12.5 mg/ml bevacizumab twice daily. Digital photographs of the cornea were taken and analyzed using an image analysis software program. On the 10th day, corneas were excised and examined histologically. Results: The mean percentage of the vascularized corneal area (%) in the control group was 63.32 ± 13.10 (mean ± SD), compared with 30.22 ± 15.73 in the subconjunctival injection group, 26.76 ± 10.23 in the 4-mg/ml topical group, and 25.52 ± 12.45 in the 12.5-mg/ml group. The differences between the control and each treatment group were significant (all p < 0.01). Further, histological examination revealed that each treatment group had fewer vessels than the control group (all p < 0.01). Conclusions: Both subconjunctival injection and topical use of bevacizumab are effective and safe in controlling corneal neovascularization.

show abstract

Inhibitory effect of triamcinolone acetonide on corneal neovascularization

Abstract: We have demonstrated that subconjunctival TA administration inhibited rabbit corneal NV. This agent may prove useful in the treatment of corneal angiogenic disorders.

Cited by 41 publications

References 31 publications

Inhibitory Effects of SU5416, a Selective Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor, on Experimental Corneal Neovascularization

Inhibitory Effects of SU5416, a Selective Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor, on Experimental Corneal Neovascularization

Drug delivery to the eye through systematic circulation following subconjonctival injection

Topical and Subconjunctival Bevacizumab for Corneal Neovascularization in an Experimental Rat Model

Contact Info

Product

Resources

About